APDL Presentation UNIDO Mentoring Program For African Pharmaceutical Companies. Germany- Bonn

Transcription

1 APDL Presentation UNIDO Mentoring Program For African Pharmaceutical Companies. Germany- Bonn A unique and successful example of starting world- class pharmaceutical manufacturing in Africa With us Life Always gets Better 1

2 Overview o Who we are o Awards & Recognitions o Vision & Footprint o Technology Used in APDL o Strength and opportunities o Regulatory compliance o Performance Review of Business o Strategies for Growth 2018 onwards o Partnership Goals With us Life Always gets Better 2

3 Abacus Parenteral Drugs Ltd. 1. A Kiboko group company 2. Largest manufacturer of Large Volume Parenterals,and Small Volume Parenterals (eye/ ear/nasal drops), using BFS technology in EAC 3. Spread over 36 acres of land and built up area is approx. 11,500 sq meters. 4. Established in 2006 and commercial production commenced in Investment of US $ 30 million. 6. Employing approx people 3

4 AWARDS The Best Investor of The Year Award 2009 Best Exporter In Pharmaceuticals 2016 &2017 With us Life Always gets Better 4

5 With us Life Always gets Better 5

6 Premium Sophisticated Technology - BFS LVP Weiller Machine Volumes of 500 ml SVP Weiller - SWFI and Eye Ear Nasal Drops 5 ml and 10 ml. LVP Rommelag Machine Volumes of 500 ml, 250 ml, 100 ml o Total Capacity LVP1 +LVP 2 per annum - 43 Millions Bottles of LVP o Total SVP Combined Capacity SWFI+EEN per annum Million Bottles of SVP With us Life Always gets Better 6

7 Regional Strengths 1. Strategically situated to deliver within 7 days within East Africa o Our logistics costs are much lower due to proximity. Delivery lead times are shorter. o No need to hold huge stocks. In case of an epidemic we can respond quickly. 2. High brand equity in the market (Abacus has been the largest distributor in Uganda with over 22 years experience) 3. Distribution support o Abacus Pharma Ltd (sister company)helps in 36% of distribution in 5 countries with 19 branches in Uganda, 5 Branches in Tanzania, 3 Branches in Bujumbura, 1 branch each in Rwanda and Kenya. o Marketing and promotion team throughout the East African region(5 countries) With us Life Always gets Better 7

8 Regional Strengths 4. Domestic Government Support o No import duty and VAT for local manufacturing o 10% additional NDA verification fee for competing imported 7 products (of APDL: D5, D50, NS, RL, ABAGYL, ABTOL 20% & CIFIN) if imported by others (to protect local manufacturers). An additional increase of up to 25% is under discussion. o Govt. of Uganda (NMS tenders) giving preference to local manufacturers by an additional 15% price preference and BUBU policy(buy Uganda, Build Uganda) o VAT refund for raw materials o 10 years tax holiday for APDL ending in Carried forward losses can be used indefinitely. With us Life Always gets Better 8

9 Opportunities 1. Markets are naturally growing ( 10%) 2. APDL enjoys regional market leadership (80% LVP Market Share in Uganda/ Rwanda/ Burundi, 50% in Tanzania and 5% in Kenya) 3. APDL is the only local manufacturer of IV Infusions/ EEN drops in: Uganda, Tanzania, Rwanda, Burundi, South Sudan, DR Congo. It is the largest IV fluids manufacturer in East Africa. 4. Only 2 IV fluid manufacturers In Kenya: Relatively smaller in capacity. Ivee Aqua and Auto Sterile. 5. Only 3 Indian Companies represented in the region: Claris, Nirlife and Mark Parenteral 6. APDL Cost Competitiveness o APDL facilities are well located for Uganda, Rwanda, Burundi, Tanzania (Mwanza), South Sudan, DR Congo due to these being land locked countries. o APDL spends less on land transportation costs. Also effectively uses the water transport through Lake Victoria. 7. Increase production capacity With us Life Always gets Better 9

10 REGULATORY COMPLIANCE CERTIFICATION QMS & GMP Accreditation VALIDITY ISO (9001:2008) MAR 2018 National Drug Authority Uganda Tanzania Food and Drugs Authority Pharmacy and poisons Board Kenya Food medicine and healthcare administration and control authority of Ethiopia. Direction de la pharmacie du medicament et des laboratoires de Cote d ivoire MAR 2020 OCT 2020 AUG 2019 APR 2021 SEP 2022 MARKETING AUTHORIZATION LVP COUNTRY Registered Submitted dossiers Registered SVP UGANDA TANZANIA KENYA RWANDA BURUNDI ETHIOPIA 7 8 ZAMBIA MALAWI 6 7 FRANCOPHONE TOTAL Submitted dossiers 10

11 PERFORMANCE REVIEW 2017 With us Life Always gets Better 11

12 1.Loyal Customers And Their Contribu9on To Total Sales ESTD. % CONTRIBUTION TO TOTAL SALES ESTD. % CONTRIBUTION TO TOTAL UNIT SALES EST.% CONTRIBUTION TO TOTAL SALES VALUE 2017 CLIENT SEGMENT WHOLESALERS UGANDA 31 % 25 % 17% DOMESTIC- PRIVATE NMS UGANDA 16 % 12 % 12% DOMESTIC- GOVT JMS UGANDA 6 % 7 % 9% DOMESTIC- PVT NGO MSD TANZANIA 13 % 28 % 30% EXPORTS- GOVT ABACUS TANZANIA 8 % 8 % 9% EXPORTS- PRIVATE ABACUS RWANDA 4 % 6 % 7% EXPORTS- PRIVATE CAMEBU BURUNDI 7 % 3 % 4% EXPORTS - GOVT ABACUS BURUNDI 2 % 2 % 3% EXPORTS- PRIVATE ABACUS KENYA 13 % 9 % 9% EXPORTS - PRIVATE 100 % DomesKc 52% + Exports 48% 100 % DOMESTIC 44 % +EXPORTS 56% 100% With Us... Life Always Gets Better 12

13 STRATEGIES FOR GROWTH 1. Optimize Product Mix By 2022 the LVP 500ml contribution will decline to 44% of revenue. The high margin LVP 100ml will grow from 15% in 2018 to 23% in 2022 of total turnover. The high value- high margin EEN products will grow from 17% in 2018 to 28% in 2022 of total turnover. No capacity increase has been taken into account in both cases With us Life Always gets Better 13

14 2. Geographical Expansion - ETHIOPIA - 15 products submitted to Ethiopia. - Business Expected: 2018/2019 USD 0.5m, 2019/2020 USD 1.0m and 2020/2021 USD 2.0m - FRANCOPHONE o Registration Report YTD products registered in Ivory Coast, B. Faso, Congo (B), and Gabon. o Expected to add USD 1.0m sales in 2018/2019. USD 2.0m in 2019/2020 and 3.0m by 2020/2021. With us Life Always gets Better 14

15 3. Formulation of New Product Development (FND) o New products to be launched in with high value and high margins which are expected to add USD 2 to 3m by Srn Product Strength Volume Market samples PMA to NDA Commercial Batch 1 Xylometazoline 0.10% 10ml 10 10/3/ /10/17 2 Ketorolac 0.50% 5 ml 10 29/3/17 05/10/17 3 Moxifloxacin 0.50% 10ml 10 21/04/17 05/10/17 4. Planning for capacity increase Additional line for Small Volume Parenterals(SVP) Capacity expected to reach 100% by PMA APPROVED PMA APPROVED PMA APPROVED Remarks LAUNCHED ON 8th NOV, 2017 With us Life Always gets Better 15

16 PARTNERSHIP GOALS o Direct Investment : - Already talking to Carlyle Group o Technology and Know- How Transfer: - Formulations for new products - Contract manufacturing - Licensure agreements o To enable us expand to other market segments including but not limited to; o High margin Ophthalmic generics o Parenteral Nutrition o Peritoneal dialysis solutions (1000ml &2000ml) o High margin LVPs especially antibiotics(100ml) o SVP Injectables With us Life Always gets Better 16

17 THANK YOU With us Life Always gets Better 17